1. Home
  2. ADPT vs AROC Comparison

ADPT vs AROC Comparison

Compare ADPT & AROC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

N/A

Current Price

$27.73

Market Cap

4.6B

Sector

Health Care

ML Signal

N/A

Logo Archrock Inc.

AROC

Archrock Inc.

N/A

Current Price

$25.65

Market Cap

5.3B

Sector

Energy

ML Signal

N/A

Company Overview

Basic Information
Metric
ADPT
AROC
Founded
2009
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Oil & Gas Production
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
4.6B
5.3B
IPO Year
2019
2007

Fundamental Metrics

Financial Performance
Metric
ADPT
AROC
Price
$27.73
$25.65
Analyst Decision
Strong Buy
Buy
Analyst Count
8
6
Target Price
$33.86
★ $42.71
AVG Volume (30 Days)
★ 2.1M
1.8M
Earning Date
11-04-2026
11-02-2026
Dividend Yield
N/A
★ 3.43%
EPS Growth
63.89
★ 74.29
EPS
N/A
★ 1.27
Revenue
$276,976,000.00
★ $1,489,818,000.00
Revenue This Year
$10.85
$0.20
Revenue Next Year
$21.60
$9.33
P/E Ratio
★ N/A
$21.09
Revenue Growth
★ 54.77
28.70
52 Week Low
$12.00
$22.91
52 Week High
$32.21
$42.23

Technical Indicators

Market Signals
Indicator
ADPT
AROC
Relative Strength Index (RSI) 49.06 35.02
Support Level $24.02 N/A
Resistance Level $29.92 $37.33
Average True Range (ATR) 1.71 1.37
MACD -0.09 -0.21
Stochastic Oscillator 31.91 0.92

Price Performance

Historical Comparison
ADPT
AROC

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

About AROC Archrock Inc.

Archrock Inc is an energy infrastructure company focused on midstream natural gas compression. It is a provider of natural gas compression services, based on total compression fleet horsepower, to customers across the United States and a supplier of aftermarket services to customers that own compression equipment. The company operates through two segments: contract operations and aftermarket services. The contract operations segment includes designing, sourcing, owning, installing, operating, servicing, repairing, and maintaining its owned fleet of natural gas compression equipment, and generates the maximum revenue. The aftermarket services segment provides operations, maintenance, overhaul, and reconfiguration services, and sales of parts and components.

Share on Social Networks: